Research Paper Volume 8, Issue 12 pp 3520—3534
Delivery of sFIT-1 engineered MSCs in combination with a continuous low-dose doxorubicin treatment prevents growth of liver cancer
Figure 6. (A) Western blot of Caspase8 that HepG2 cells were either treated with saline, 0.02μM doxorubicin, sFlt1, or 0.02μM doxorubicin plus sFlt1 for 48 h. Pro-caspase bands are marked by an (*), whereas Caspase8 are labeled by arrows. (B)Caspase8 knockdown clone (HepG2.shc8) and control clone (HepG2.shctrl) were treated with doxorubicin plus sFlt1 before the apoptosis was measured. The apoptosis of HepG2.shc8 was decreased. *p < 0.05, vs sFlt1 plus 0.02μM doxorubicin group.